CN113855642A - Blood sugar reducing sustained release tablet and preparation method thereof - Google Patents
Blood sugar reducing sustained release tablet and preparation method thereof Download PDFInfo
- Publication number
- CN113855642A CN113855642A CN202111411967.5A CN202111411967A CN113855642A CN 113855642 A CN113855642 A CN 113855642A CN 202111411967 A CN202111411967 A CN 202111411967A CN 113855642 A CN113855642 A CN 113855642A
- Authority
- CN
- China
- Prior art keywords
- parts
- release tablet
- powder
- blood sugar
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 71
- 210000004369 blood Anatomy 0.000 title claims abstract description 71
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 39
- 230000001603 reducing effect Effects 0.000 title abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims description 57
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 48
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 47
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 47
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 47
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 47
- 235000019359 magnesium stearate Nutrition 0.000 claims description 24
- 239000003826 tablet Substances 0.000 claims description 24
- 240000000249 Morus alba Species 0.000 claims description 21
- 235000008708 Morus alba Nutrition 0.000 claims description 21
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 235000017803 cinnamon Nutrition 0.000 claims description 17
- 239000008101 lactose Substances 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- 239000004925 Acrylic resin Substances 0.000 claims description 13
- 229920000178 Acrylic resin Polymers 0.000 claims description 13
- 244000013123 dwarf bean Species 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 235000021278 navy bean Nutrition 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 37
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000291 postprandial effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 239000003392 amylase inhibitor Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 150000004283 biguanides Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
The invention provides a blood sugar reducing sustained release tablet and a preparation method thereof. Clinical test results show that the effective rate of reducing blood sugar reaches 100% after the sustained-release tablet for reducing blood sugar is taken for 12 weeks, the effect of controlling blood sugar of patients in the early stage of diabetes is obvious, the patients can be prevented from further developing diabetes, and fasting blood sugar is reduced by 49.7% after the sustained-release tablet is taken with the medicine for 12 weeks.
Description
Technical Field
The invention belongs to the technical field of biological products, and particularly relates to a blood sugar reducing sustained-release tablet and a preparation method thereof.
Background
Diabetes is a metabolic disease caused by insufficient insulin secretion, and is characterized in that blood sugar is higher than a standard value for a long time, and a patient has typical symptoms of more eating, more drinking, more urine and weight loss, i.e., more than three and one less. Diabetes is a systemic endocrine-metabolic disease that, once suffered, requires lifelong treatment. Failure to treat diabetes effectively in a timely manner can lead to serious complications such as cardiovascular disease, stroke, chronic kidney disease, and retinopathy. The vast majority of patients with diabetes fall into type II diabetes, which is primarily the result of being overweight and lacking physical activity.
At present, diabetics mostly control sugar and blood sugar from the following aspects, 1. in terms of diet, the diabetics can control the blood sugar through reasonable diet, and in life, diet control is the basis for treating diabetes, and diet control and sufficient nutrition are needed to keep ideal body weight; 2. when the health-care product is properly exercised, the blood sugar can be effectively reduced, the cardiovascular condition can be improved, the blood pressure and the blood fat can be reduced, and the psychological state can be improved; 3. the oral medication can be used for treating diabetes mellitus by selecting drugs for many patients after the patients suffer from the diabetes mellitus, clinically, the oral medication can be used for treating the diabetes mellitus, and sulfonylureas hypoglycemic drugs are used. The other is biguanide hypoglycemic medicine, which has the main functions of reducing blood sugar and treating diabetes by inhibiting the recovery of glucose from intestinal tract and promoting the decomposition of glucose in tissue; 4. insulin therapy. The existing hypoglycemic drug is released quickly after being taken by a patient, reduces the blood sugar level in the body of the patient or releases slowly, controls blood sugar fluctuation for a long time, and simultaneously, the hypoglycemic drug is taken before meals, the patient does not take food in time, possibly causes hypoglycemia symptoms by the taken drug, and affects the body health of the patient. Although functional foods for realizing sugar control are available in the market at present, the effect of reducing and controlling sugar for diabetics and obese people is not obvious.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides the blood sugar reducing sustained release tablet which can effectively control the blood sugar of the patient at the early stage of diabetes and prevent the patient from further developing into the patient with diabetes; can be used in combination with medicine for effective sugar control of diabetic; the medicine has obvious effect on obese people and people needing to control sugar. Comprises the following components of mulberry leaf powder, cinnamon powder, navy bean powder, hydroxypropyl methylcellulose, microcrystalline cellulose and lactose.
Mulberry leaf powder: the Shennong herbal Jing records that the mulberry leaf is cold in nature and sweet and bitter in taste, has the functions of dispelling wind and heat, clearing lung and moistening dryness, and improving eyesight, is called as the folium mori, has the effects of nourishing yin and supplementing blood, benefiting liver and ventilating, and reducing blood pressure and inducing diuresis, and the Shennong herbal Jing records that the mulberry leaf is a medicine for treating hand-foot yangming, is decocted to obtain a decoction for replacing tea, can stop thirst and improve eyesight and grow hair, wherein the thirst is the symptom of relieving diabetes.
Cinnamon powder: shen nong Ben Cao Jing: the medicine has pungent and warm taste, mainly treats all diseases, nourishes spirit, harmonizes color, benefits joints, and tonifies middle-jiao and Qi. The medicines are engaged for relieving the bowels firstly, and the spirit is relieved after long-term administration, so that the body is light and not old. The face is bright and beautiful, and the eyebrows are as good as children. "compendium of materia Medica": to strengthen the muscles and bones and to activate blood vessels, all the herbs should be led, so long-term administration is not so old. Wherein the active substance type-A polymer can promote the metabolic decomposition of blood sugar by stimulating the release of islet beta cells, and the active substance in cinnamon can produce the anti-diabetic effect by stimulating the release of islet beta cells, improving the sensitivity of internal insulin and reducing the glucose intake in intestines.
White kidney bean powder: the white kidney bean powder-alpha amylase inhibitor can block starch from being decomposed into maltose, thereby having the function of regulating and controlling blood sugar. Alpha-amylase inhibitors are present in the protein component of legumes, which protein binds to the active site of alpha-amylase and prevents the metabolic activity of starch, and thus it is also known as a "starch absorption blocker", and navy bean extract reduces digestion of human starch and 94% to 99.9% of the intestinal amylase activity, controlling postprandial blood glucose elevation and postprandial insulin levels.
Hydroxypropyl methyl cellulose (HPMC) has the following properties: it has excellent cold water solubility, and is basically insoluble in hot water of over 60 deg.c and can only expand. ② it is a non-ionic cellulose ether, its solution has no ionic charge and does not react with metal salt or ionic organic compound, so that it can ensure that it does not react with other auxiliary material in the course of preparation production. And thirdly, the drug has stronger anti-sensitivity, and the anti-sensitivity is also increased along with the increase of the substitution degree in the molecular structure, and the drug taking HPMC as the auxiliary material has more stable quality than the drug adopting the traditional auxiliary materials (starch, dextrin and powdered sugar). And fourthly, the solution viscosity is stable to acid and alkali, the viscosity change is not large when the solution is stored for a long time within the range of pH 3-11, and the pH of a 1% aqueous solution is 4-8. After the derivatives with different viscosities are mixed according to different proportions, the viscosities of the derivatives change according to a certain rule, and the linear relation is good, so that the derivatives can be adjusted and selected as required. The gel controls water diffusion and drug release, and the gel strength is affected by the viscosity, concentration and chemical properties of the polymer. Surface activity, the molecular structure of the auxiliary materials has hydrophilic and oleophilic groups, so that the surface tension is reduced after the auxiliary materials are prepared into a solution, and the effects of increasing emulsification and surface activity are achieved. Sixthly, the medicine has metabolic inertia, and is not metabolized and not absorbed as a pharmaceutic adjuvant, so that heat is not provided in the medicine, and the medicine is a safe pharmaceutic adjuvant. HPMC has the advantages that HPMC does not have other auxiliary materials, so that HPMC is one of the most used pharmaceutical auxiliary materials at home and abroad at present. HPMC is used as retarder, controlled release agent and pore-forming agent, and the high viscosity model is used for preparing retarder and controlled release agent of mixed material skeleton sustained release tablet and hydrophilic gel skeleton sustained release tablet; the low viscosity model of the pore-forming agent for sustained or controlled release tablets allows such formulations to rapidly achieve a first dose of therapeutic effect and then be sustained or controlled to maintain an effective blood concentration.
Preferably, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose K100 and hydroxypropyl methylcellulose E15. The invention adopts hydroxypropyl methylcellulose as the controlled release agent of the blood sugar reducing sustained release tablet.
Any of the above schemes preferably further comprises acrylic resin and magnesium stearate, and the magnesium stearate can be replaced by other forming agents.
In any of the above embodiments, preferably, the acrylic resin is an acrylic No. 4 resin.
In any of the above schemes, the blood sugar reducing sustained release tablet preferably comprises, by weight, 500 parts of mulberry leaf powder 200-.
In any of the above schemes, the blood sugar reducing sustained release tablet preferably comprises, by weight, 500 parts of mulberry leaf powder, 100 parts of cinnamon powder, 200 parts of white kidney bean powder, 40-150 parts of hydroxypropyl methyl cellulose K100100-300 parts, 1550-100 parts of hydroxypropyl methyl cellulose E, 50-100 parts of acrylic acid No. 4 resin, 10-100 parts of microcrystalline cellulose, 10-100 parts of lactose and 6-20 parts of magnesium stearate.
In any of the above schemes, the blood sugar reducing sustained release tablet preferably comprises, by weight, 500 parts of mulberry leaf powder, 100 parts of cinnamon powder, 100 parts of white kidney bean powder, 100 parts of hydroxypropyl methyl cellulose K100300 parts, 1550 parts of hydroxypropyl methyl cellulose E, 50 parts of No. 4 acrylic resin, 50 parts of microcrystalline cellulose, 50 parts of lactose and 18 parts of magnesium stearate.
In any of the above schemes, the blood sugar reducing sustained release tablet preferably comprises, by weight, 450 parts of mulberry leaf powder, 100 parts of cinnamon powder, 50 parts of navy bean powder, 100 parts of hydroxypropyl methyl cellulose K100300 parts, 1550 parts of hydroxypropyl methyl cellulose E, 50 parts of No. 4 acrylic resin, 150 parts of microcrystalline cellulose, 50 parts of lactose and 18 parts of magnesium stearate.
In any of the above schemes, the blood sugar reducing sustained release tablet preferably comprises, by weight, 500 parts of mulberry leaf powder, 150 parts of cinnamon powder, 50 parts of navy bean powder, 100 parts of hydroxypropyl methyl cellulose K100150 parts, 1550 parts of hydroxypropyl methyl cellulose E, 110 parts of No. 4 acrylic resin, 150 parts of microcrystalline cellulose, 40 parts of lactose and 18 parts of magnesium stearate.
In any of the above schemes, the blood sugar reducing sustained release tablet preferably comprises, by weight, 400 parts of mulberry leaf powder, 150 parts of cinnamon powder, 40 parts of navy bean powder, K100350 parts of hydroxypropyl methyl cellulose, 1550 parts of hydroxypropyl methyl cellulose, 150 parts of microcrystalline cellulose, 40 parts of lactose and 18 parts of magnesium stearate.
In any of the above schemes, the blood sugar reducing sustained release tablet preferably comprises, by weight, 350 parts of mulberry leaf powder, 200 parts of cinnamon powder, 50 parts of navy bean powder, 100 parts of hydroxypropyl methyl cellulose K100300 parts, 1560 parts of hydroxypropyl methyl cellulose E, 50 parts of No. 4 acrylic resin, 150 parts of microcrystalline cellulose, 40 parts of lactose and 18 parts of magnesium stearate.
The other aspect of the invention also provides a preparation method of the blood sugar reducing sustained release tablet, which comprises the steps of mixing the materials except the magnesium stearate, performing wet granulation by using 50% ethanol, drying and granulating at 50-60 ℃, mixing and tabletting the magnesium stearate, and controlling the tablet weight to be 1.2 g/tablet.
Has the advantages that:
1. the effective rate of the blood sugar reducing sustained release tablet provided by the invention reaches 100% after 12 weeks of tests, the blood sugar control effect on patients in early stage of diabetes is remarkable, and the blood sugar reducing sustained release tablet can prevent further development of diabetes.
2. The fasting blood sugar of the blood sugar reducing sustained-release tablet provided by the invention is reduced by 49.7% after 12 weeks of use test of the blood sugar reducing sustained-release tablet in combination with hypoglycemic drugs.
3. The invention can effectively control sugar for obese people.
Drawings
FIG. 1 is a graph showing fasting blood glucose values before and after the test in group A test observation group and control group according to a preferred embodiment of the present invention;
FIG. 2 is the postprandial blood glucose values before and after the test of the group A test observation group and the control group according to the preferred embodiment of the present invention;
FIG. 3 shows the total effective rate of the group A test observation group and the control group according to the preferred embodiment of the present invention;
FIG. 4 is fasting blood glucose values before and after the test of the group B test observation group and the control group according to the preferred embodiment of the present invention;
FIG. 5 shows the postprandial blood glucose levels before and after the test in the group B test observation group and the control group according to the preferred embodiment of the present invention.
Detailed Description
The present invention will be further described with reference to the following specific examples, but the present invention is not limited to the following examples.
Example 1
A sugar-reducing sustained-release tablet adopts the following specific formula:
the preparation method comprises the following steps:
mixing the materials except magnesium stearate, wet granulating with 50% ethanol, oven drying at 50-60 deg.C, grading, mixing magnesium stearate and tabletting, wherein the tablet weight is 1.2 g/tablet.
1. Mixing folium Mori powder, cortex Cinnamomi powder, semen navy bean powder, hydroxypropyl methylcellulose K100, hydroxypropyl methylcellulose E15, acrylic acid No. 4 resin, microcrystalline cellulose and lactose at above ratio.
2. Ethanol solution with 50 percent of volume fraction is prepared as the adhesive.
3. Adding into a granulator to obtain wet granules.
4. Drying and granulating.
5. And (4) mixing, adding magnesium stearate, mixing for a certain time, and collecting the total mixed granules.
6. Adding the total mixed particles into a tabletting machine for tabletting.
Example 2
Different from the embodiment 1, the preparation method is the same as the embodiment 1.
Example 3
Different from the embodiment 1, the preparation method is the same as the embodiment 1.
| Components | Content (mg)/tablet |
| Mulberry leaf powder | 500 |
| Cinnamon powder | 150 |
| White kidney bean powder | 50 |
| Hydroxypropyl methylcellulose K100 | 150 |
| Hydroxypropyl methylcellulose E15 | 50 |
| Acrylic acid No. 4 resin | 110 |
| Microcrystalline cellulose | 150 |
| Lactose | 40 |
| Magnesium stearate | 18 |
Example 4
Different from the embodiment, the preparation method is the same as the embodiment 1, except that the content of the specific components is different.
| Components | Content (mg)/tablet |
| Mulberry leaf powder | 400 |
| Cinnamon powder | 150 |
| White kidney bean powder | 40 |
| Hydroxypropyl methylcellulose K100 | 350 |
| Hydroxypropyl methylcellulose E15 | 50 |
| Microcrystalline cellulose | 150 |
| Lactose | 40 |
| Magnesium stearate | 18 |
Example 5
Different from the embodiment, the preparation method is the same as the embodiment 1, except that the content of the specific components is different.
| Components | Content (mg)/tablet |
| Mulberry leaf powder | 350 |
| Cinnamon powder | 200 |
| White kidney bean powder | 50 |
| Hydroxypropyl methylcellulose K100 | 300 |
| Hydroxypropyl methylcellulose E15 | 60 |
| Acrylic acid No. 4 resin | 50 |
| Microcrystalline cellulose | 150 |
| Lactose | 40 |
| Magnesium stearate | 18 |
Example 6
Different from the embodiment 1, the composition comprises 500 parts of 200-200 parts of mulberry leaf powder, 300 parts of 100-100 parts of cinnamon powder, 40-200 parts of navy bean powder, 50-400 parts of hydroxypropyl methyl cellulose K10050, 1550-200 parts of hydroxypropyl methyl cellulose E, 0-200 parts of No. 4 acrylic resin, 10-200 parts of microcrystalline cellulose, 10-150 parts of lactose and 6-24 parts of magnesium stearate.
Example 7
Different from the embodiment 1, the composition comprises 500 parts of mulberry leaf powder, 200 parts of cinnamon powder, 40-150 parts of navy bean powder, 100-300 parts of hydroxypropyl methyl cellulose K100100, 1550-100 parts of hydroxypropyl methyl cellulose E, 50-100 parts of acrylic acid No. 4 resin, 10-100 parts of microcrystalline cellulose, 10-100 parts of lactose and 6-20 parts of magnesium stearate.
Example 8
Clinical tests were conducted on the blood sugar-decreasing sustained-release tablets prepared in example 1.
Firstly, testing population: 192 volunteers were collected, 82 pre-diabetic patients who met the inclusion criteria and 110 diabetic patients.
1. Sex distribution: 101 male and 91 female
2. Age distribution: age 33-67 years, average 48 years
3. Inclusion criteria were: populations meeting the IFG, IGT and diabetes criteria in the table below.
Remarking: IFG and IGT are collectively referred to as pre-diabetes; fasting state means that there is no food calories for at least 8 hours.
Second, test method
The test persons were divided into 2 groups according to the inclusion criteria. Group A was pre-diabetic patients for 82 total tests, group B was diabetic patients for 110 total tests.
1. Group a test one:
(1) grouping: the pre-diabetic 82 patients were randomized into 2 groups. Group 41 persons were observed, and group 41 persons were controlled.
(2) Taking the hypoglycemic composition:
firstly, after the test of observation group personnel is started, the blood sugar reducing sustained-release tablet (1.2 g/tablet) is taken 30 minutes before lunch every day, 1 tablet is taken every day, and scientific diet and exercise (at least 150min per week) are paid attention to simultaneously for 12 weeks.
② after the test of the control group, the ordinary sugar-reducing tablet candy (0.6 g/tablet) is taken 10 minutes before meal every day, the ordinary sugar-reducing tablet candy does not contain hydroxypropyl methylcellulose, 3 times every day, 2 tablets every time, and the scientific diet and exercise (at least 150min per week) are paid attention to for 12 weeks.
(3) And (3) blood sugar measurement:
firstly, all testers carry out 4 blood sugar measurements before the test, 4 weeks after the test, 8 weeks after the test and 12 weeks after the test;
secondly, measuring fasting blood sugar before breakfast and blood sugar after lunch for 2h each time, and taking the mean value after 2 measurements.
2. Test two in group B:
(1) grouping: diabetic patients 110 were randomly divided into 2 groups. Group 55 persons were observed, control group 55 persons.
(2) Taking the hypoglycemic composition:
firstly, after the observation group personnel test starts, the blood sugar reducing sustained-release tablets (1.2 g/tablet, 1 time per day and 1 tablet per time) are taken 30 minutes before lunch every day, meanwhile, the blood sugar reducing drug metformin (orally taken 15min before meal, 3 times per day and 0.5mg per time) is continuously taken, and scientific diet and exercise (at least 150min per week) are paid attention to for 12 weeks.
② after the test of the control group, the ordinary sugar-reducing tablet candy (0.6 g/tablet, 3 times per day, 2 tablets each time) is taken 10 minutes before the meal every day, and simultaneously the sugar-reducing drug metformin (oral administration 15min before the meal, 3 times per day, 0.5mg each time) is continuously taken, and scientific diet and exercise (at least 150min per week) are paid attention for 12 weeks.
(3) And (3) blood sugar measurement:
firstly, all testers perform blood glucose measurement for 3 times before the test starts, 4 weeks after the test, 8 weeks after the test and 12 weeks after the test;
secondly, measuring fasting blood sugar before breakfast and blood sugar after lunch for 2h each time, and taking the mean value after 2 measurements.
Third, evaluation criteria
1. The effect is shown: fasting blood glucose dropped to the normal range (<6.1mmol/L) and 2h post-prandial blood glucose dropped to the normal range (<7.8mmol/L) after treatment;
2. the method has the following advantages: after treatment, the fasting blood sugar is reduced by more than 0.5mmol/L or the blood sugar is reduced by more than 1.0mmol/L after 2h of meal;
3. and (4) invalidation: the blood sugar drop does not meet the above standard.
4. Total effective rate (effective + significant)/total number of cases × 100%.
Fourth, test results
1. Group A test 1
2. Test two in group B:
conclusion of the experiment
1. As can be seen from the group A, the effective rate of the blood sugar reducing sustained-release tablets (observation group) after 12 weeks of the test reaches 100%, the blood sugar control effect on patients in the early stage of diabetes is remarkable, the further development of diabetes can be prevented, and the prevention effect of the blood sugar reducing sustained-release tablets is higher than that of the common blood sugar reducing tablets (control group).
2. As can be seen from the second test in group B, after 12 weeks of the test, the fasting blood sugar of the blood sugar reducing sustained-release tablets (observed group) is reduced by 49.7 percent, which is better than 43.6 percent of that of the common blood sugar reducing tablets (control group), and the blood sugar is reduced by 44.6 percent and is better than 41.7 percent after 2 hours.
In conclusion, the blood sugar reducing sustained-release tablet prepared by the invention can be used for diabetics and early-stage patients, has obvious blood sugar reducing effect on both of the diabetics and the early-stage patients, and has better effect than that of common blood sugar reducing tablet candies.
It will be appreciated by those skilled in the art that the present invention includes any combination of the above summary and detailed description sections, is limited by space and is not described in any way as to what constitutes a combination for the sake of brevity and clarity of description. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A blood sugar lowering sustained release tablet comprises folium Mori powder, cortex Cinnamomi powder, semen Cistanchis powder, hydroxypropyl methylcellulose, microcrystalline cellulose, and lactose.
2. The sugar-reducing sustained-release tablet according to claim 1, wherein the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose K100 and hydroxypropyl methylcellulose E15.
3. The sugar-reducing sustained-release tablet according to claim 2, further comprising acrylic resin and magnesium stearate.
4. The sugar-reducing sustained-release tablet according to claim 3, wherein the acrylic resin is acrylic resin No. 4.
5. The sugar-reducing sustained-release tablet as claimed in claim 4, which comprises, by weight, 500 parts of mulberry leaf powder 200-.
6. The sugar-reducing sustained-release tablet as claimed in claim 4, which comprises, by weight, 500 parts of mulberry leaf powder 300-.
7. The sugar-reducing sustained-release tablet according to claim 4, which comprises, by weight, 500 parts of mulberry leaf powder, 100 parts of cinnamon powder, 100 parts of white kidney bean powder, 100 parts of hydroxypropyl methyl cellulose K100300 parts, 1550 parts of hydroxypropyl methyl cellulose E, 50 parts of No. 4 acrylic resin, 50 parts of microcrystalline cellulose, 50 parts of lactose and 18 parts of magnesium stearate.
8. The sugar-reducing sustained-release tablet according to claim 4, which comprises, by weight, 450 parts of mulberry leaf powder, 100 parts of cinnamon powder, 50 parts of navy bean powder, 100 parts of hydroxypropyl methyl cellulose K100300 parts, 1550 parts of hydroxypropyl methyl cellulose E, 50 parts of No. 4 acrylic resin, 150 parts of microcrystalline cellulose, 50 parts of lactose and 18 parts of magnesium stearate.
9. The sugar-reducing sustained-release tablet according to claim 4, which comprises, by weight, 500 parts of mulberry leaf powder, 150 parts of cinnamon powder, 50 parts of navy bean powder, 100 parts of hydroxypropyl methyl cellulose K100150 parts, 1550 parts of hydroxypropyl methyl cellulose E, 110 parts of No. 4 acrylic resin, 150 parts of microcrystalline cellulose, 40 parts of lactose and 18 parts of magnesium stearate.
10. A process for preparing the hypoglycemic slow-release tablet as claimed in any one of claims 1-9, which includes mixing the materials except magnesium stearate, wet granulating with 50% alcohol, baking at 50-60 deg.C, granulating, mixing magnesium stearate and tabletting, and features low cost and 1.2 g/tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111411967.5A CN113855642A (en) | 2021-11-25 | 2021-11-25 | Blood sugar reducing sustained release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111411967.5A CN113855642A (en) | 2021-11-25 | 2021-11-25 | Blood sugar reducing sustained release tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113855642A true CN113855642A (en) | 2021-12-31 |
Family
ID=78985320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111411967.5A Pending CN113855642A (en) | 2021-11-25 | 2021-11-25 | Blood sugar reducing sustained release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113855642A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101444245A (en) * | 2007-11-26 | 2009-06-03 | 天津市金圭谷木糖醇有限公司 | Mulberry leaf chewing tablet with sugar-lowering function |
| CN102166258A (en) * | 2010-11-23 | 2011-08-31 | 天津市尖峰天然产物研究开发有限公司 | Preparation method of slow-release micropill with mulberry leaf extract |
| CN104383123A (en) * | 2014-11-14 | 2015-03-04 | 程金生 | Method for preparing golden camellia lipid-lowering blood sugar-reducing preparation |
| CN109010299A (en) * | 2018-09-30 | 2018-12-18 | 北京济全生物科技有限公司 | A kind of sustained release hypoglycemic medicine composition and its preparation method and application |
| CN110917272A (en) * | 2019-12-25 | 2020-03-27 | 北京辨证堂中医药研究院 | Traditional Chinese medicine formula for curing diabetes and complications thereof |
| CN113384654A (en) * | 2021-07-21 | 2021-09-14 | 张学记 | Hypoglycemic composition and preparation method and application thereof |
-
2021
- 2021-11-25 CN CN202111411967.5A patent/CN113855642A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101444245A (en) * | 2007-11-26 | 2009-06-03 | 天津市金圭谷木糖醇有限公司 | Mulberry leaf chewing tablet with sugar-lowering function |
| CN102166258A (en) * | 2010-11-23 | 2011-08-31 | 天津市尖峰天然产物研究开发有限公司 | Preparation method of slow-release micropill with mulberry leaf extract |
| CN104383123A (en) * | 2014-11-14 | 2015-03-04 | 程金生 | Method for preparing golden camellia lipid-lowering blood sugar-reducing preparation |
| CN109010299A (en) * | 2018-09-30 | 2018-12-18 | 北京济全生物科技有限公司 | A kind of sustained release hypoglycemic medicine composition and its preparation method and application |
| CN110917272A (en) * | 2019-12-25 | 2020-03-27 | 北京辨证堂中医药研究院 | Traditional Chinese medicine formula for curing diabetes and complications thereof |
| CN113384654A (en) * | 2021-07-21 | 2021-09-14 | 张学记 | Hypoglycemic composition and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 吴旖主编, 广东高等教育出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN113384654A (en) | Hypoglycemic composition and preparation method and application thereof | |
| CN102872423B (en) | Traditional Chinese medicine compound for treating glycuresis and preparation method thereof | |
| CN102319341A (en) | Chinese medicinal compound for treating and preventing diabetes | |
| CN101773624A (en) | Traditional Chinese medicine composition for curing diabetes and preparation method thereof | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN1127349C (en) | Antilipemic slimming tea prepn | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN113855642A (en) | Blood sugar reducing sustained release tablet and preparation method thereof | |
| CN105535553A (en) | Formula for regulating blood sugar of human body | |
| CN1286503C (en) | Combination of Chinese traditional medicine possessing function of regulating blood sugar, blood fat, preparation method | |
| US11744870B2 (en) | Traditional Chinese medicine composition for treating metabolic syndrome and preparations thereof | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN109010621A (en) | A kind of Chinese medicine composition that treating diabetes, preparation method and applications | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes | |
| CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
| CN101491584A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN102366481B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN105663772A (en) | Drug for treating diabetes mellitus | |
| CN117018105A (en) | Traditional Chinese medicine composition for treating impaired glucose tolerance and preparation method thereof | |
| CN110302266A (en) | A kind of hypoglycemic composition and preparation method thereof | |
| CN111617201A (en) | A Chinese medicinal composition for treating diabetes, and its preparation method | |
| CN109966368A (en) | A kind of Chinese medicine composition for treating diabetes, preparation method and preparation | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN107737262A (en) | A kind of health-oriented products with auxiliary hyperglycemic effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211231 |
|
| RJ01 | Rejection of invention patent application after publication |